Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status:
Recruiting
Trial end date:
2026-07-30
Target enrollment:
Participant gender:
Summary
Background:
Glioblastoma is a type of brain cancer. Treatments include radiation, chemotherapy, and
surgery. But survival rates are poor. Researchers think that the drug selinexor, when
combined with chemotherapy and radiation, might help.
Objective:
To learn the highest dose of selinexor that people with brain cancer can tolerate when given
with temozolomide and radiation therapy.
Eligibility:
People ages 18 and older with brain cancer that has not been treated with chemotherapy or
radiation
Design:
Participants will be screened under another protocol.
Before participants start treatment, they will have tests:
Neurological and physical evaluations
Blood and urine tests
Possible CT scan or MRI of the brain if they have not had one in 3 weeks. Participants will
lie in a machine that takes pictures of the body. They may have a dye injected into a vein.
Surveys about their well-being
Participants will have radiation to the brain for up to 6 weeks. This will usually be given
once a day, Monday through Friday.
Starting the second day of radiation, participants will take selinexor by mouth once a week.
They will take it in weeks 1, 2, 4, and 5. The timing may be changed.
Starting the first day of radiation, participants will take temozolomide by mouth once a day
until they complete radiation.
Participants will have blood tests once per week during treatment.
Participants will have a follow-up visit 1 month after they complete treatment. Then they
will have visits at least every 2 months for the first 2 years, then at least every 3 months
for another year. Visits will include MRIs and blood tests.
...